Suppr超能文献

使用实验设计(DoE)开发通用纳米结构脂质载体(NLC)-第二部分:丁卡因与不同表面活性剂的包封及稳定性

Development of a Versatile Nanostructured Lipid Carrier (NLC) Using Design of Experiments (DoE)-Part II: Incorporation and Stability of Butamben with Different Surfactants.

作者信息

Matarazzo Ananda P, Rios Carlos A, Gerônimo Gabriela, Ondei Roberta, de Paula Eneida, Breitkreitz Márcia C

机构信息

Faculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas 13083-871, SP, Brazil.

Institute of Chemistry, University of Campinas (UNICAMP), Campinas 13083-862, SP, Brazil.

出版信息

Pharmaceutics. 2024 Jun 27;16(7):863. doi: 10.3390/pharmaceutics16070863.

Abstract

Nanostructured lipid carriers (NLCs) are typically composed of liquid lipids, solid lipids, and surfactants, enabling the encapsulation of lipophilic drugs. Butamben is a Class II anesthetic drug, according to the Biopharmaceutical Classification System (BCS); it has a log P of 2.87 and is considered a 'brick dust' (poorly water-soluble and poorly lipid-soluble) drug. This characteristic poses a challenge for the development of NLCs, as they are not soluble in the liquid lipid present in the NLC core. In a previous study, we developed an NLC core consisting of a solid lipid (Crodamol CP), a lipophilic liquid with medium polarity (SR Lauryl lactate), and a hydrophilic excipient (SR DMI) that allowed the solubilization of 'brick dust' types of drugs, including butamben. In this study, starting from the NLC core formulation previously developed we carried out an optimization of the surfactant system and evaluated their performance in aqueous medium. Three different surfactants (Crodasol HS HP, Synperonic PE/F68, and Croduret 40) were studied and, for each of them, a 2 factorial design was stablished, with total lipids, % surfactant, and sonication time (min) as the input variables and particle size (nm), polydispersity index (PDI), and zeta potential (mV) as the response variables. Stable NLCs were obtained using Crodasol HS HP and Synperonic PE/F68 as surfactants. Through a comparison between NLCs developed with and without SR DMI, it was observed that besides helping the solubilization of butamben in the NLC core, this excipient helped in stabilizing the system and decreasing particle size. NLCs containing Crodasol HS HP and Synperonic PE/F68 presented particle size values in the nanometric scale, PDI values lower than 0.3, and zeta potentials above |10|mV. Concerning NLCs' stability, SBTB-NLC with Synperonic PE/F68 and butamben demonstrated stability over a 3-month period in aqueous medium. The remaining NLCs showed phase separation or precipitation during the 3-month analysis. Nevertheless, these formulations could be freeze-dried after preparation, which would avoid precipitation in an aqueous medium.

摘要

纳米结构脂质载体(NLCs)通常由液体脂质、固体脂质和表面活性剂组成,能够包封亲脂性药物。布坦苯是一种根据生物药剂学分类系统(BCS)划分的II类麻醉药物;其log P值为2.87,被认为是一种“砖粉”(水溶性差且脂溶性差)药物。这一特性给NLCs的开发带来了挑战,因为它们不溶于NLC核心中存在的液体脂质。在先前的一项研究中,我们开发了一种由固体脂质(Crodamol CP)、中等极性的亲脂性液体(SR月桂醇乳酸酯)和亲水性辅料(SR DMI)组成的NLC核心,该核心能够使包括布坦苯在内的“砖粉”类药物溶解。在本研究中,我们从先前开发的NLC核心配方出发,对表面活性剂体系进行了优化,并评估了它们在水性介质中的性能。研究了三种不同的表面活性剂(Crodasol HS HP、Synperonic PE/F68和Croduret 40),并针对每种表面活性剂建立了一个二因素设计,将总脂质、表面活性剂百分比和超声处理时间(分钟)作为输入变量,粒径(纳米)、多分散指数(PDI)和zeta电位(毫伏)作为响应变量。使用Crodasol HS HP和Synperonic PE/F68作为表面活性剂获得了稳定的NLCs。通过比较添加和不添加SR DMI开发的NLCs,观察到除了有助于布坦苯在NLC核心中溶解外,这种辅料还有助于稳定体系并减小粒径。含有Crodasol HS HP和Synperonic PE/F68的NLCs呈现纳米级的粒径值、低于0.3的PDI值和高于|10|毫伏的zeta电位。关于NLCs的稳定性,含有Synperonic PE/F68和布坦苯的SBTB-NLC在水性介质中3个月内表现出稳定性。其余的NLCs在3个月的分析过程中出现了相分离或沉淀。然而,这些制剂在制备后可以冻干,这将避免在水性介质中沉淀。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e86/11280378/b82c36a3f35c/pharmaceutics-16-00863-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验